CARB-X

The Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) is a nonprofit partnership focused on supporting antibacterial research.[1][2] CARB-X was launched in summer of 2016 at the Boston University School of Law, where CARB-X Executive Director Professor Kevin Outterson teaches health law, corporate law, and co-directs the Health Law Program.[3]

In March 2021 CARB-X awarded grants worth a total of $24 million US dollars to 11 companies to fund research.[4]

References
  1. Alm, Richard A.; Gallant, Karen (2020-06-12). "Innovation in Antimicrobial Resistance: The CARB-X Perspective". ACS Infectious Diseases. 6 (6): 1317–1322. doi:10.1021/acsinfecdis.0c00026.
  2. "New money flows to CARB-X for antimicrobials". Nature Biotechnology. 36 (7): 560–560. 2018-08-01. doi:10.1038/nbt0718-560. ISSN 1546-1696.
  3. "CARB-X Global Partnership". Boston University. Retrieved 2021-06-18.
  4. Grose, Thomas K. (2017). "Rx FOR SUPERBUGS". ASEE Prism. 27 (2): 32–36. ISSN 1056-8077.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.